Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer

NCT04294264 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT04294264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04294264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 12, 2019
Completion date
March 27, 2026
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, recurrent colon carcinoma, refractory colorectal carcinoma, stage iv colon cancer ajcc v7, stage iva colon cancer ajcc v7, stage ivb colon cancer ajcc v7